Tigemonam是第一个口服单环β-内酰胺抗生素。其抗菌谱广,超过目前所应用的口服青霉素类和头孢菌素类抗生素,抗菌活性强,在≤1μg/ml时即可抑制大多数的大肠埃希氏菌、克雷伯氏菌、产气肠杆菌、柠檬酸菌、变形杆菌、普罗威登氏菌、嗜水气单孢菌、沙门氏菌属、粘质沙雷氏菌和小肠结肠炎那森氏菌。在≤0.25μg/ml时可抑制嗜血杆菌属、奈瑟氏菌属和粘膜炎布兰汉氏菌。Tigemonam抗菌活性优于头孢氨苄和羟氨苄青霉素-克拉维酸,对许多耐甲氧苄氨嘧啶-SMX和庆大霉素的肠道杆菌也有抑 Tigemonam is the first oral monocyclic beta-lactam antibiotic. Its antibacterial spectrum wide, more than the current application of oral penicillins and cephalosporins antibiotics, antibacterial activity at ≤ 1μg / ml to inhibit the majority of Escherichia coli, Klebsiella, gas Enterobacter, Citrobacter, Proteus, Providencia, Aeromonas hydrophila, Salmonella, Serratia marcescens, and Enterocolitis. In ≤ 0.25μg / ml can inhibit Haemophilus, Neisseria and M. catarrhalis bacteria. Tigemonam antibacterial activity superior to cephalexin and amoxicillin - clavulanic acid, for many methicillin-SMX and gentamycin-resistant enterobacter also